Celldex Therapeutics Inc.

NASDAQ:CLDX   3:59:46 PM EDT
26.54
-1.14 (-4.12%)
Earnings Announcements

Celldex Reports 80% Complete Response Rate In Interim Data Update From Phase 1B Study Of CDX-0159 In Chronic Inducible Urticaria

Published: 03/29/2021 11:29 GMT
Celldex Therapeutics Inc. (CLDX) - Celldex Reports 80% Complete Response Rate in Interim Data Update From Phase 1b Study of Cdx-0159 in Chronic Inducible Urticaria.
Celldex Therapeutics Inc - Cdx-0159 Generally Well Tolerated to Date.
Celldex Therapeutics Inc - Anticipate Results From Ongoing Phase 1b Study in Chronic Spontaneous Urticaria by End of This Year.
Celldex Therapeutics Inc - Are on Track to Initiate a Third Study in Prurigo Nodularis in Q4.
Revenue is expected to be $0.97 Million
Adjusted EPS is expected to be -$0.35

Next Quarter Revenue Guidance is expected to be $0.97 Million
Next Quarter EPS Guidance is expected to be -$0.36

More details on our Analysts Page.